Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide in pediatric SHPT and CKD on hemodialysis
NCT03633708Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Apr 2019
- Primary completion
- Jan 2029
- Countries
- 10
01
Overview
A Phase 3 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Started Apr 2019; status: recruiting.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03633708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633708.